uremic pruritus. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: Intervention group: Fumaria Parviflora capsule produced by Shiraz School of Pharmacy, administer two capsules before breakfast, lunch and dinner (300 mg Fmaria Parviflora powder in eac
Treatment - Drugs
Placebo
Intervention group: Fumaria Parviflora capsule produced by Shiraz School of Pharmacy, administer two capsules before breakfast, lunch and dinner (300 mg Fmaria Parviflora powder in each capsule) for 8
Control group: Placebo capsule produced by Shiraz School of Pharmacy, administer two capsules before breakfast, lunch and dinner for 8 weeks.
Sponsors
Vice chancellor for research of Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: hemodialysis patients older than18 years old with itching more than 6 weeks; VAS score equal or more than 4; patients with hemodialysis twice or three times a week; patients should took at least a course of antipruritic treatment with no proper response. Exclusion criteria: liver disease; respiratory disease; kt/V less than 1.2; convulsion history; any dermatologic disease that induce itching; hemolytic disease; malignancies; cholestasis; hepatitis B or C infection; presence of anemia with hemoglubin less than 10 .
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duo score. Timepoint: before and after intervention and weekly during intervention period. Method of measurement: by questionnair and calculating score.;Visual analogue scale. Timepoint: before and after intervention and weekly during intervention period. Method of measurement: visual analogue scale ruler. | — |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin4. Timepoint: Before and after intervention. Method of measurement: with Interleukin4 ELISA kit.;Interferon gama. Timepoint: Before and after intervention. Method of measurement: with Interferon gama ELISA Kit.;HsCRP. Timepoint: Before and after intervention. Method of measurement: with hsCRP ELISA kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRahimeh Akrami
Shiraz University of Medical Sciences
Outcome results
None listed